LD Micro Conference - Companies

NovaBay Pharmaceuticals (NBY), a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance.

Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white blood cells. The company is developing commercial opportunities for its portfolio of anti-infective Aganocide compounds in four healthcare markets, including dermatology, ophthalmology, urology, and hospital infections.

Its lead product candidate, NVC-422, is used for the treatment of adenoviral conjunctivitis, a type of ‘Pink Eye’; killing of P. acne, the bacterium associated with inflamed acne lesions, and other known dermal pathogens; and treatment of uropathogens, including Proteus mirabilis, a gram-negative bacterium that can cause urinary catheter blockage and encrustation.

The company is also developing NVC-101, an acidic composition of hypochlorous acid to promote wound healing, tissue repair, and tissue regeneration.

NovaBay Pharmaceuticals has a licensing and research collaboration agreement with Alcon Manufacturing Ltd. for use of its Aganocide compounds in the eye, ear, and sinus infections, as well as for contact lens solutions; and with Galderma S.A. to develop and commercialize its Aganocide compounds in acne, impetigo, and other dermatological indications.

The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007.

NovaBay Pharmaceuticals was incorporated in 2000 and is based in Emeryville, California.

Information provided by Capital IQ.